Skip to main content
PCVX logo

PCVX · Vaxcyte, Inc. · Metrics

Track PCVX — free
$60.16 +1.64 (+2.80%) Play latest call Q4 2025 earnings call transcript
Market Cap
$9.26B
Shares
158.30M
Volume · Nov 19 172.87K Avg daily vol (3M) 2.16M

PCVX metrics

69 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$58.52
Market cap
$9.26B

Price action

23 metrics
Price change (1W)
-14.7%
Price change (30D)
-8.1%
Price change (3M)
-7.6%
Price change (6M)
+24.1%
Price change (YTD)
+26.8%
Price change (1Y)
+18.2%
Trailing year
Price change (5Y)
+138.6%
52-week high
$73.82
52-week low
$43.06
Change from 52-week high
-20.7%
Change from 52-week low
+35.9%
Annualized volatility
56.0%
Annualized volatility (3M)
79.4%
Implied volatility (30D)
52.7%
IV rank (1Y)
14.9
IV percentile (1Y)
33.3
Beta
1.3
RSI (14D)
41.7
Price vs SMA 50
-5.9%
Price vs SMA 200
+1.3%
Avg volume (3M)
2.16M
Relative volume
0.5
Average dollar volume
$138.89M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
158.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.7
reciprocal yield 26.9%
FCF yield
-10.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-05

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$1.23B
Net income (TTM)
−$1.15B
Trailing 12 months
Diluted EPS (TTM)
$-8.07
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-8.66
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-8.07
Operating cash flow per diluted share (TTM)
$-6.77
Free cash flow per diluted share (TTM)
$-6.86
Capital expenditures per diluted share (TTM)
$0.09
R&D per diluted share (TTM)
$7.69
Stock compensation per diluted share (TTM)
$1.10
Book value per share
$20.49

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-46.1%
Return on assets
-38.4%
Debt / equity
—
Current ratio
4.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$974.42M
Quick ratio
4.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.29B
Latest balance sheet
Cash & equivalents
$125.47M
Total assets
$2.99B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$962.01M
Capital expenditures (TTM)
$12.41M
R&D (TTM)
$1.09B
SG&A (TTM)
—
Stock compensation (TTM)
$156.30M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
356
13F filer change QoQ
+23
Institutional ownership
107.3%
Conviction holders (share of 13F filers)
2.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.4%
Holder tenure
17.8
Price vs estimated holder cost
+8.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.9%

Short interest

3 metrics
Short interest
9.7%
Latest settlement · 6.7 days to cover
Days to cover
6.7d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$5.19M
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1649094 CUSIP 92243G108 13F (30d) 372 filings 338 filers Visit website Investor relations